Generex Biotechnology Corporation has developed a proprietary platform drug delivery technology, RapidMist™, that administers medications directly into the mouth as a metered-dose spray, for rapid absorption by the buccal mucosa. This technology has been specially designed for the pain-free, accurate, and safe delivery of drugs. The Company's flagship product, Generex Oral-lyn™, is the first application for RapidMist and is currently in late stage clinical trials around the world.

Antigen Express, Inc., a subsidiary of Generex, is a platform and product-based company developing proprietary vaccine formulations for large, unmet medical needs. Their focus is on stimulating critical members of the immune response, known as T helper cells. For more information regarding Antigen Express, please visit www.antigenexpress.com